FONDATION-IPSEN
23.5.2017 07:32:05 CEST | Business Wire | Press release
The Fondation IPSEN (1) contributes to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians. The Fondation IPSEN Endocrine Regulations Prize (2) will be presented today at the ECE (European Congress of Endocrinology) in Lisbon. An international jury (3) chaired by Professor Iain Robinson (National Institute for Medical Research, London, UK ), awarded the prize to Bruce Mc Ewen for his pioneering work on glucocorticoids, stress and neuronal degeneration.
The Fondation IPSEN(1) contributes to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians from different backgrounds. Created in 2002, the Endocrine Regulations Prize(2) of the Fondation IPSEN awards renowned specialists who made breakthrough discoveries or significant progress in the field. Pr Bruce McEwen has been awarded by an international jury(3) for his pioneering work on glucocorticoids, stress and neuronal degeneration. The prize will be presented at the ECE (European Congress of Endocrinology), followed by a lecture given by Bruce McEwen.
During his talk, Bruce McEwen will discuss about the role of the steroid
hormones that are produced in the brain which mediate every aspect of
brain function. This has broadened the definition of
‘neuroendocrinology’ to include the reciprocal communication between the
brain and the body via hormonal and neural pathways.
The brain is
the central organ of stress and adaptation to stress because it
perceives and determines what is threatening, as well as the behavioural
and physiological responses to the stressor. The adult and developing
brain possess remarkable structural and functional plasticity in
response to stress, including neuronal replacement, dendritic
remodelling, and synapse turnover. Stress causes an imbalance of neural
circuitry subserving cognition, decision-making, anxiety and mood. This
imbalance, in turn, affects systemic physiology via neuroendocrine,
autonomic, immune and metabolic mediators. In the short term, as for
increased fearful vigilance and anxiety in a threatening environment,
these changes may be adaptive. But, if the danger passes and the
behavioural state persists along with the changes in neural circuitry,
such maladaptation may need intervention with a combination of
pharmacological and behavioural therapies, as is the case for chronic
anxiety and depression. Moreover, adverse early-life experience, produce
lasting effects on brain and body over the life-course via epigenetic
mechanisms. While prevention is most important, the plasticity of the
brain gives hope for therapies that take into consideration brain–body
interactions.
Biography
Bruce S. McEwen obtained his Ph.D. in Cell
Biology in 1964 from The Rockefeller University.
He is a member
of the US National Academy of Sciences, the National Academy of
Medicine, and the American Academy of Arts and Sciences. He served as
President of the Society for Neuroscience in 1997-98. As a
neuroscientist and neuroendocrinologist, McEwen studies
environmentally-regulated, variable gene expression in brain, mediated
by circulating steroid hormones and endogenous neurotransmitters in
relation to brain sexual differentiation and the actions of sex and
stress hormones on the adult brain. His laboratory discovered adrenal
steroid receptors in the hippocampus in 1968 that was the gateway for
discovering effects of circulating hormones on cognitive function, mood
regulation and other CNS functions. His laboratory combines molecular,
anatomical, pharmacological, physiological and behavioral methodologies
and relates their findings to human clinical information. His current
research focuses on stress effects on amygdala and prefrontal cortex, as
well as hippocampus, and his laboratory also investigates sex hormone
effects and sex differences in these brain regions involved in cognitive
function and mood regulation. He served on the MacArthur Foundation
Research Network on Socioeconomic Status and Health, in which he has
helped to reformulate concepts and measurements related to stress and
stress hormones in the context of human societies. This led to the
concept of “allostatic load and overload” that describes the wear and
tear on the body and brain from chronic stress and related life style
behaviors that lead to dysregulation of physiological stress pathways
that are normally protective.
He is also a member of the National
Council on the Developing Child which focuses on biological embedding of
early life experiences and promoting healthy brain development.
He
is the co-author of a book with science writer, Elizabeth Lasley, for a
lay audience called “The End of Stress as We Know It”, published in
2002, and “The Hostage Brain” with science writer, the late Harold M.
Schmeck, Jr., published in 1994.
(1) The Fondation IPSEN
Established in 1983 under the
aegis of the Fondation de France, the ambition of the Fondation IPSEN is
to initiate a reflection about the major scientific issues of the
forthcoming years. The long-standing mission of the Fondation IPSEN is
to contribute to the development and dissemination of scientific
knowledge by fostering interaction between scientists and clinicians. It
has developed an important international network of scientific experts
who meet regularly at meetings known as Colloques Médecine et
Recherche
, dedicated to three main topics: neurosciences,
endocrinology and cancer science. Moreover the Fondation IPSEN has
started several series of meetings in partnership with the Salk
Institute, the Karolinska Institute as well as with the journals Cell
and Science
. The Fondation IPSEN produced several hundred
publications and more than 250 scientists have been awarded prizes and
grants.
www.fondation-ipsen.org
(2) The Endocrine Regulations Prize laureates
Created
in 2002, this Prize of
the Fondation Ipsen
has been
awarded to following the renowned specialists: Wylie VALE
(2002), Robert
LEFKOWITZ
(2003), Pierre CHAMBON
(2004), Thomas HÖKFELT
(2005), Roger CONE
(2006), William CROWLEY
(2007), Ronald
EVANS
(2008), Gilbert VASSART
(2009), Shlomo MELMED
(2010), Paolo SASSONE-CORSI
(2011), Jeffrey M. FRIEDMAN
(2012), Bert O’MALLEY
(2013), Maria I. NEW
(2014), C.
Ronald Kahn
(2015) and John W. FUNDER
(2016).
(3) Members of the jury
Iain ROBINSON
(National
Institute for Medical Research, London, UK)
, President
Xavier
BERTAGNA
(Hôpital Cochin, Paris, France)
Felipe
CASANUEVA
(University of Santiago de Compostela, Santiago de
Compostela, Spain)
Michael CONN
(Texas Tech
University Health Sciences Center, El Paso, USA)
Ezio GHIGO
(Ospedale Molinette, Turin, Italy)
Ilpo HUHTANIEMI
(Imperial
College Faculty of Medicine, London, UK)
Gérard KARSENTY
(Columbia
University Medical Center, New York, USA)
Paul KELLY
(Faculté
de Médecine Necker Enfants Malades, Paris, France)
Stafford
LIGHTMAN
(University of Bristol, Bristol, UK)
Günter
STALLA
(Max Planck Institute of Psychiatry, München, Germany
Phyllis
WISE
(University of Illinois, Urbana, USA).
View source version on businesswire.com: http://www.businesswire.com/news/home/20170522005878/en/
Contact:
Fondation IPSEN
Yannick TANGUY, Tel. : +33 (0)1 58 33 50 00
E-mail
: fondation@ipsen.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
